GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases

Do GLP-1 receptor agonists enhance the effectiveness of progestins in reducing endometrial cancer (EC) risk among patients with nonmalignant uterine conditions?In this cohort study with 444 820 participants, combined GLP-1RA with progestin was associated with a significantly lower risk of developing EC compared with progestin alone, across subgroups stratified by body mass index, age, baseline risk level, and progestin route.These results suggest that adding GLP-1RAs to progestin therapy in women with benign uterine diseases or hyperplasia may be associated with reduced EC risk.

Corresponding Authors: Edward J. Tanner, MD, MBA, Professor of Gynecologic Oncology, Johns Hopkins University, 1800 Orleans St, Baltimore, MD 21287 (etanner4@jh.edu); James Cheng-Chung Wei, MD, PhD, Department of Allergy, Immunology jccwei@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.